Pulmatrix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulmatrix, Inc. on February 7, 2019. The filing discloses the entry into a Material Definitive Agreement for a registered direct offering of common stock and a concurrent private placement of warrants. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $2.5 million from the sale of 1,706,484 shares of common stock at $1.465 per share.
- Net Proceeds: Expected to be approximately $2.15 million after deducting placement agent fees, expenses, and offering costs.
- Use of Proceeds: Working capital and general corporate purposes.
- Placement Agent Fees: 7.0% cash fee plus a 1.0% management fee on gross proceeds.
- Warrant Issuance:
- Common Warrants: 1,706,484 warrants issued to purchasers (1:1 ratio), exercisable at $1.34 per share, terminating 5.5 years from issuance.
- Placement Agent Warrants: 110,922 warrants issued to H.C. Wainwright & Co., LLC, exercisable at $1.8313 per share, terminating 5 years from issuance.
Material Changes and Transaction Terms
The company entered into a Securities Purchase Agreement with institutional investors. The transaction includes a 15-day lock-up period prohibiting the issuance of additional equity, unless the closing bid price of the common stock reaches or exceeds $1.95 for two consecutive trading days. The closing of the offering is expected to occur on or around February 12, 2019, subject to customary conditions.
Outlook, Risks, and Management Commentary
The filing states that the representations and warranties in the Purchase Agreement are for risk allocation between parties and should not be relied upon as statements of fact regarding the company's condition. The company intends to use the net proceeds to support working capital needs. No specific financial guidance or revenue outlook was provided in this filing.
Key Facts for Investor Verification
- Verify the actual closing date of the offering (expected February 12, 2019) and confirmation of fund receipt.
- Monitor the stock price relative to the $1.95 threshold to determine if the 15-day lock-up on new issuances is lifted early.
- Review the impact of the 1,706,484 new shares and potential warrant exercises on existing shareholder dilution.
- Confirm the final net proceeds after all transaction expenses are settled.